Genetics of myeloid malignancies:: Pathogenetic and clinical implications

被引:260
作者
Fröhling, S
Scholl, C
Gilliland, DG
Levine, RL
机构
[1] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA
[3] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany
关键词
D O I
10.1200/JCO.2005.05.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Myeloid malignancies are clonal disorders that are characterized by acquired somatic mutation in hematopoietic progenitors. Recent advances in our understanding of the genetic basis of myeloid malignancies have provided important insights into the pathogenesis of acute myeloid leukemia (AML) and myeloproliferative diseases (MPD) and have led to the development of novel therapeutic approaches. In this review, we describe our current state of understanding of the genetic basis of AML and MPD, with a specific focus on pathogenetic and therapeutic significance. Specific examples discussed include RAS mutations, KIT mutations, FLT3 mutations, and core binding factor rearrangements in AML, and JAK2 mutations in polycythemia vera, essential thrombocytosis, and chronic idiopathic myelofibrosis.
引用
收藏
页码:6285 / 6295
页数:11
相关论文
共 188 条
[1]   Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution [J].
Abe, A ;
Emi, N ;
Tanimoto, M ;
Terasaki, H ;
Marunouchi, T ;
Saito, H .
BLOOD, 1997, 90 (11) :4271-4277
[2]   Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia [J].
Abu-Duhier, FM ;
Goodeve, AC ;
Wilson, GA ;
Care, RS ;
Peake, IR ;
Reilly, JT .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) :983-988
[3]   POLYCYTHEMIA-VERA - STEM-CELL AND PROBABLE CLONAL ORIGIN OF DISEASE [J].
ADAMSON, JW ;
FIALKOW, PJ ;
MURPHY, S ;
PRCHAL, JF ;
STEINMANN, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 295 (17) :913-916
[4]   The leukemic protein core binding factor β (CBFβ)-smooth-muscle myosin heavy chain sequesters CBFα2 into cytoskeletal filaments and aggregates [J].
Adya, N ;
Stacy, T ;
Speck, NA ;
Liu, PP .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (12) :7432-7443
[5]   Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit [J].
Akin, C ;
Brockow, K ;
D'Ambrosio, C ;
Kirshenbaum, AS ;
Ma, YS ;
Longley, BJ ;
Metcalfe, DD .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (08) :686-692
[6]   Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression [J].
Alland, L ;
Muhle, R ;
Hou, H ;
Potes, J ;
Chin, L ;
SchreiberAgus, N ;
DePinho, RA .
NATURE, 1997, 387 (6628) :49-55
[7]   Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta [J].
Apperley, JF ;
Gardembas, M ;
Melo, JV ;
Russell-Jones, R ;
Bain, BJ ;
Baxter, J ;
Chase, A ;
Chessells, JM ;
Colombat, M ;
Dearden, CE ;
Dimitrijevic, S ;
Mahon, FX ;
Marin, D ;
Nikolova, Z ;
Olavarria, E ;
Silberman, S ;
Schultheis, B ;
Cross, NCP ;
Goldman, JM .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :481-487
[8]   MLL-rearranged leukemias:: Insights from gene expression profiling [J].
Armstrong, SA ;
Golub, TR ;
Korsmeyer, SJ .
SEMINARS IN HEMATOLOGY, 2003, 40 (04) :268-273
[9]   Occurrence of myeloproliferative disorder in patients with Noonan syndrome [J].
BaderMeunier, B ;
Tchernia, G ;
Mielot, F ;
Fontaine, JL ;
Thomas, C ;
Lyonnet, S ;
Lavergne, JM ;
Dommergues, JP .
JOURNAL OF PEDIATRICS, 1997, 130 (06) :885-889
[10]   BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics:: a Cancer and Leukemia Group B Study [J].
Baldus, CD ;
Tanner, SM ;
Ruppert, AS ;
Whitman, SP ;
Archer, KJ ;
Marcucci, G ;
Caligiuri, MA ;
Carroll, AJ ;
Vardiman, JW ;
Powell, BL ;
Allen, SL ;
Moore, JO ;
Larson, RA ;
Kolitz, JE ;
de la Chapelle, A ;
Bloomfield, CD .
BLOOD, 2003, 102 (05) :1613-1618